• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Alcohol consumption inversely related to risk of developing Multiple Sclerosis

bys25qthea
January 7, 2014
in Chronic Disease, Neurology
Reading Time: 2 mins read
Naltrexone reduces drinking in alcoholics with post-traumatic stress disorder
Share on FacebookShare on Twitter

Image: PD

1. Swedish adults who reported the highest amount of alcohol consumption had a decreased incidence of Multiple Sclerosis (MS).

Evidence grade: Level 3 (Average)

Study Rundown: MS is a chronic neurologic disease which is thought to have both environmental and genetic influences. Alcohol consumption is a modifiable environmental exposure which has, in other studies, been shown to have a protective factor against certain autoimmune diseases, such as autoimmune hypothyroidism, systemic lupus erythematosus, and rheumatoid arthritis. This study was designed to help determine whether a similar relationship exists between alcohol consumption and risk of developing MS. The results of the study demonstrated that participants with MS were less likely to be alcohol consumers compared to those without MS, who were more likely to be alcohol consumers.

Strengths include a large sample size of cases and controls that were randomly selected. The investigators also ensured that only properly filled out questionnaires were included in the final analysis. Weaknesses of the study include the fact that only Swedish people were included in the study. There was also a long list of environmental factors that were included in the questionnaire, which could have confounded the results.

Click to read the study in JAMA Neurology

RELATED REPORTS

Deficits in executive function are not universal among patients with alcohol use disorder

Few interventions improve posthospitalization follow-up for alcohol use disorder

Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates

Relevant Reading: Caffeine and alcohol intakes have no association with risk of multiple sclerosis

In-Depth [case control study]: The study consisted of two case control studies from Sweden, Epidemiological Investigation of Multiple Sclerosis (EIMS) and Genes and Environment in Multiple Sclerosis (GEMS). While the questionnaires for the two studies were different, they both inquired about the participants’ alcohol consumption over a period of time. EIMS included 745 MS cases and 1761 controls, and GEMS included 5874 MS cases and 5246 controls.

In EIMS, women who reported high alcohol consumption had an OR of 0.6 (95% CI, 0.4-1.0) of developing MS compared to women who did not consume alcohol. Men with high alcohol consumption had an OR of 0.5 (95% CI, 0.2-1.0) compared to men who did not consume alcohol. In GEMS, the OR for women was 0.7 (95% CI, 0.6-0.9) and for men, it was 0.7 (95% CI, 0.5-0.9). Risk reduction was more pronounced in smokers than never smokers in the GEMS group (attributable proportion, 0.2; P=0.01).

By Anees Daud and James Jiang

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: Alcoholmultiple sclerosis
Previous Post

Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients

Next Post

Transcutaneous bilirubinometry linked to decreased serum testing and costs [Pediatrics Classics Series]

RelatedReports

Chronic Disease

Deficits in executive function are not universal among patients with alcohol use disorder

September 15, 2026
Chronic Disease

Few interventions improve posthospitalization follow-up for alcohol use disorder

September 14, 2026
Chronic Disease

Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates

June 2, 2025
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Tolebrutinib reduces disability progression in nonrelapsing secondary progressive multiple sclerosis

June 5, 2025
Next Post

Transcutaneous bilirubinometry linked to decreased serum testing and costs [Pediatrics Classics Series]

Worldwide smoking prevalence decreasing as number of smokers increases

Worldwide smoking prevalence decreasing as number of smokers increases

Adolescent smoking heavily influenced by parents and siblings

Varenicline and buproprion more effective than varenicline alone for tobacco abstinence

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Brepocitinib becomes first oral therapy approved for adult dermatomyositis
  • An ultrasound-guided percutaneous method of vagal nerve stimulation may be effective for refractory chronic pain
  • Daraxonrasib extends survival in metastatic pancreatic cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.